Arcus Biosciences Reports Promising Casdatifan Results: 35% Response Rate and Robust Disease Control in Kidney Cancer Study

Key Efficacy Milestone: Casdatifan Shows 35% Confirmed Response Rate and Median Progression-Free Survival Not Yet Reached in Lead Cohort

Arcus Biosciences (NYSE:RCUS) has unveiled new clinical data at an investor event, spotlighting its HIF-2a inhibitor, casdatifan, for the treatment of metastatic clear cell renal cell carcinoma (ccRCC). In a pivotal cohort using the Phase 3 100mg tablet dose, casdatifan delivered a confirmed overall response rate (ORR) of 35%, with a median progression-free survival (mPFS) that had not yet been reached, even after a median follow-up of one year. For context, these outcomes outpace published data from studies involving the only marketed HIF-2a inhibitor in similar settings, hinting at the potential for a best-in-class profile.

Durable Outcomes and Disease Control in a Heavily Pretreated Population

The Phase 1/1b ARC-20 study included 121 patients, most of whom had progressed through at least two prior lines of therapy. Notably, more than half had received three or more previous treatments. The pooled analysis of all four dose cohorts demonstrated an mPFS of 12.2 months and an 18-month landmark PFS of 43%—again exceeding prior benchmarks. Disease control rates (patients achieving either partial response or stable disease) stood at 84% for the 100mg tablet group and 81% for the entire study population. Among responders, 74% remained on treatment at the time of data cutoff, reflecting impressive durability.

Acceptable Safety Profile with Low Rates of Discontinuation

No new safety concerns emerged, with casdatifan demonstrating an acceptable and manageable risk profile across all doses. In the lead cohort, 31% experienced serious treatment-emergent adverse events (TEAEs), with the most common grade 3 or higher events being anemia (25%) and hypoxia (9%). Only 9% of patients discontinued treatment due to adverse effects in both the lead cohort and the overall pooled group.

Pipeline Expansion: Arcus Announces Five Inflammation and Autoimmune Programs

In a significant strategic development, Arcus is advancing five research programs targeting autoimmune and inflammatory diseases. First-in-human studies are expected to begin in 2026, with preclinical candidates focused on high-impact indications like atopic dermatitis, rheumatoid arthritis, psoriasis, and more. This broadening of the company’s pipeline leverages Arcus’s drug discovery expertise beyond oncology into large-market immunology.

Arcus Retains Full Rights to Casdatifan; Strategic Collaboration with Gilead Continues on Other Programs

Importantly, Arcus maintains full development and commercialization rights to casdatifan after Gilead’s option rights to the molecule expired. The two companies continue to collaborate on other oncology and inflammatory disease assets, with significant potential milestone payments and profit-sharing on the table for new developments.

What Should Investors Watch For?

The combination of encouraging casdatifan data, the retention of full rights, and pipeline expansion into immunology could mark a pivotal moment for Arcus. While results look promising, direct cross-trial comparisons always carry caveats. The Phase 3 PEAK-1 study, additional data readouts, and progression on inflammatory programs are key events to monitor. For now, Arcus’s position as a potential leader in both kidney cancer and immune-mediated diseases has never looked clearer.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI